DelistingMay 21, 2026, 08:29 PM
Liminatus Pharma Receives Nasdaq Delisting Notice
AI Summary
Liminatus Pharma announced it received a delisting notice from The Nasdaq Stock Market LLC due to non-compliance with the $50,000,000 market value of listed securities (MVLS) rule and the $15,000,000 market value of publicly held shares (MVPHS) rule. The company had until May 18, 2026, to regain compliance but failed to do so. Trading of its securities will be suspended on May 29, 2026, unless an appeal is filed by May 27, 2026. Liminatus intends to timely request an appeal, which will stay the delisting action.
Key Highlights
- Liminatus Pharma received a delisting notice from Nasdaq on May 20, 2026.
- Company failed to comply with the $50,000,000 market value of listed securities (MVLS) rule.
- Also failed to comply with the $15,000,000 market value of publicly held shares (MVPHS) rule.
- The 180-day compliance period for these rules ended on May 18, 2026.
- Trading of common stock and warrants will be suspended on May 29, 2026, if no appeal is filed.
- Liminatus intends to request an appeal before the Nasdaq Hearings Panel by May 27, 2026.
- The appeal request will result in a stay of any suspension or delisting action.
Price Impact
More from LIMN